SG10201909382UA - Glyt1 inhibitors for use in the treatment of hematological disorders - Google Patents

Glyt1 inhibitors for use in the treatment of hematological disorders

Info

Publication number
SG10201909382UA
SG10201909382UA SG10201909382UA SG10201909382UA SG 10201909382U A SG10201909382U A SG 10201909382UA SG 10201909382U A SG10201909382U A SG 10201909382UA SG 10201909382U A SG10201909382U A SG 10201909382UA
Authority
SG
Singapore
Prior art keywords
treatment
hematological disorders
glyt1 inhibitors
glyt1
inhibitors
Prior art date
Application number
Other languages
English (en)
Inventor
Daniela Alberati
Annette Koerner
Emmanuel Pinard
Michael Winter
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of SG10201909382UA publication Critical patent/SG10201909382UA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG10201909382U 2014-04-30 2015-04-27 Glyt1 inhibitors for use in the treatment of hematological disorders SG10201909382UA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14166497 2014-04-30

Publications (1)

Publication Number Publication Date
SG10201909382UA true SG10201909382UA (en) 2019-11-28

Family

ID=50677958

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201608397UA SG11201608397UA (en) 2014-04-30 2015-04-27 Glyt1 inhibitors for use in the treatment of hematological disorders
SG10201909382U SG10201909382UA (en) 2014-04-30 2015-04-27 Glyt1 inhibitors for use in the treatment of hematological disorders

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201608397UA SG11201608397UA (en) 2014-04-30 2015-04-27 Glyt1 inhibitors for use in the treatment of hematological disorders

Country Status (18)

Country Link
US (1) US9877963B2 (tr)
EP (1) EP3137073B1 (tr)
JP (1) JP6283766B2 (tr)
KR (1) KR101869185B1 (tr)
CN (1) CN106163520B (tr)
AR (1) AR100209A1 (tr)
CY (1) CY1120508T1 (tr)
ES (1) ES2683184T3 (tr)
HR (1) HRP20181205T1 (tr)
MA (1) MA39927B1 (tr)
MY (1) MY189930A (tr)
PH (1) PH12016501784A1 (tr)
PT (1) PT3137073T (tr)
RS (1) RS57535B1 (tr)
SG (2) SG11201608397UA (tr)
SI (1) SI3137073T1 (tr)
TR (1) TR201809598T4 (tr)
WO (1) WO2015165842A1 (tr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3199156A1 (de) * 2016-02-01 2017-08-02 Heinrich-Heine-Universität Düsseldorf Verwendung von glycin-transporter-1-antagonisten als zentralnervöse analgetika
CU20200106A7 (es) * 2018-06-20 2021-08-06 Axcella Health Inc Composiciones y métodos para el tratamiento de hemoglobinopatías y talasemias
AU2021205510A1 (en) 2020-01-09 2022-07-21 Disc Medicine, Inc. Methods of treating erythropoietic protoporphyria, X-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibitors
EP4304597A1 (en) * 2021-03-12 2024-01-17 Disc Medicine, Inc. Compositions and methods for treating anemia associated with a ribosomal disorder
AU2022273051A1 (en) * 2021-05-14 2023-12-07 Disc Medicine, Inc. Methods of treating erythropoietic protoporphyria, x-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibitors
CA3220741A1 (en) * 2021-05-27 2022-12-01 Disc Medicine, Inc. Methods of treating erythropoietic protoporphyria, x-linked protoporphyria, or congenital erythropoietic porphyria with a solid form of bitopertin
WO2023235326A1 (en) * 2022-05-31 2023-12-07 Disc Medicine, Inc. Compositions and methods for treating hepatic porphyrias with glycine transport inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME00116B (me) * 2003-08-11 2010-10-10 Hoffmann La Roche Piperazin sa ili supstituisanom fenil grupom i njihova upotreba kao inhibitora glyt1
DE602006010665D1 (en) * 2005-02-07 2010-01-07 Hoffmann La Roche Heterocyclsche substituierte phenylmethanone als inhibitoren des glycintransporters 1

Also Published As

Publication number Publication date
KR20160130517A (ko) 2016-11-11
US20170042888A1 (en) 2017-02-16
CN106163520A (zh) 2016-11-23
MA39927B1 (fr) 2018-09-28
HRP20181205T1 (hr) 2018-09-21
PT3137073T (pt) 2018-07-27
EP3137073A1 (en) 2017-03-08
ES2683184T3 (es) 2018-09-25
MY189930A (en) 2022-03-22
JP2017511385A (ja) 2017-04-20
WO2015165842A1 (en) 2015-11-05
CN106163520B (zh) 2019-12-13
US9877963B2 (en) 2018-01-30
MA39927A (fr) 2017-03-08
KR101869185B1 (ko) 2018-06-19
EP3137073B1 (en) 2018-06-06
RS57535B1 (sr) 2018-10-31
PH12016501784B1 (en) 2016-11-07
SG11201608397UA (en) 2016-11-29
PH12016501784A1 (en) 2016-11-07
AR100209A1 (es) 2016-09-21
CY1120508T1 (el) 2019-07-10
SI3137073T1 (sl) 2018-09-28
TR201809598T4 (tr) 2018-07-23
JP6283766B2 (ja) 2018-02-21

Similar Documents

Publication Publication Date Title
AU2018236800B2 (en) DNA-PK inhibitors
SG10201909382UA (en) Glyt1 inhibitors for use in the treatment of hematological disorders
WO2014028600A3 (en) 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
WO2016004068A8 (en) Hydrogel compositions comprising encapsulated cells and methods of use thereof
IN2015DN01156A (tr)
SG10201909545XA (en) Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
WO2014179564A8 (en) Thiazolopyrrolidine inhibitors of ror-gamma
WO2014062720A3 (en) Methods of treating cancer
NZ628294A (en) Compositions and methods of use of phorbol esters for the treatment of stroke
IN2014DN10386A (tr)
MX2015011898A (es) Compuestos de pirazolo y usos de los mismos.
EA201692526A1 (ru) Замещенные [1,2,4]триазольные соединения
MY189912A (en) Substituted xanthines and methods of use thereof
EA201692525A1 (ru) Замещенные соединения [1,2,4]триазола и имидазола в качестве фунгицидов
NZ630615A (en) Thiadiazolidinediones as gsk-3 inhibitors
MA39710A (fr) Composition topique destinée à être utilisée dans le traitement d'une maladie inflammatoire de l'intestin
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
MX2016003823A (es) Inhibidor selectivo de fosfatidil-inositol 3-cinasa-gamma.
EA201692289A1 (ru) Замещенные [1,2,4]триазольные и имидазольные соединения в качестве фунгицидов
PH12016500495A1 (en) Compositions for the treatment of hypertension and/or fibrosis
WO2013169631A3 (en) Wnt protein signalling inhibitors
WO2014186450A3 (en) Highly potent inhibitors of porcupine
MX363385B (es) Métodos para el tratamiento de enfermedad de células falciformes y otras condiciones inflamatorias.
EP2964750A4 (en) METHOD AND COMPOSITIONS FOR TREATING AND / OR PREVENTING TYPE-1 DIABETES
EP2994156A4 (en) Compounds, compositions and methods for the treatment of diseases through inhibiting tgf- activity